Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

University Centre of General Dermatology and Oncodermatology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland Faculty of Medicine, Wroclaw University of Science and Technology, ...

The cause of mycosis fungoides is unknown and, with the possible exception of very early stage disease, no cure is available. Fortunately, patients with MF have a number of therapeutic options and ...

Mycosis fungoides was the first type of lymphoma to be treated with radiation (Scholz, 1902). Since its use in the early 1900s, technical advances have led to the development of electron beam ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter clinical trial published in the Journal of Clinical Oncology.

including the most common subtypes mycosis fungoides and Sézary syndrome, were given DD-cxdl for five consecutive days every 21 days. Roughly 36% of patients responded to the treatment ...

New Brunswick Health Minister John Dornan says four drugs were identified under the National Strategy for Drugs for Rare Diseases: Poteligeo, for the treatment of mycosis fungoides or Sézary syndrome; ...

The first step in this bilateral agreement will be to deliver funding to support the province for the following four drugs under the National Strategy for Drugs for Rare Diseases: Poteligeo, for the ...